FDA approves Genentech’s Ocrevus Zunovo

Genentech, a member of the Roche Group, announced that the United States Food and Drug Administration has approved Ocrevus Zunovo for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis. “Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options,” the company stated. “Ocrevus Zunovo gives patients and providers another option for receiving Ocrevus, building on a decade of robust safety and efficacy data for Ocrevus in multiple sclerosis. Today’s approval may offer greater flexibility for healthcare providers and people living with multiple sclerosis, based on their individual treatment needs,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development.